|
Market Closed -
Nasdaq
01:30:00 22/08/2026 am IST
|
5-day change | 1st Jan Change | ||
| 439.33 USD | +1.88% |
|
+5.81% | +34.22% |
| 21/08 | FTC Challenges Amgen's Patent Play in Enbrel Antitrust Case | DJ |
| 20/08 | Piper Sandler Adjusts Price Target on Amgen to $457 From $427, Maintains Overweight Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 24TCr | |||||
| 1,11900Cr | |||||
| 65TCr | - | - | - | ||
| 47TCr | |||||
| 37TCr | |||||
| 30TCr |
- Stock Market
- Stocks
- AMGN Stock
- Charts Amgen Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
